



Premature termination of a Clinical Trial

Full title of the clinical Trial: Open-label single arm phase II study on pembrolizumab for recurrent primary central nervous system lymphoma (PCNSL)

EudraCT Number: 2015-005103-89

Sponsor: Medical University of Vienna
Represented by (name): Univ. Prof. Dr. Matthias Preusser

Reason for premature termination of the clinical trial: Unfortunately, this study was stopped after the inclusion of two (2) patients.

Study results: Therefor the formal statistical methods for inference e.g. Binomial's test, 95% confidence intervals, etc.) are not applicable in the final statistical report and we cannot achieve any statistical conclusions.

Date and Signature of Sponsor representative:

Univ.Prof. Dr. PREUSSER MATTHIAS

22. JUNI 2022